MicroRNA-187 induces diffuse large B-cell lymphoma cell apoptosis via targeting BCL6

被引:27
作者
Huang, Fang [1 ]
Jin, Yaofeng [2 ]
Wei, Yafeng [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Clin Lab, 157 West 5th Rd, Xian 710004, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Clin Pathol, Xian 710004, Shaanxi, Peoples R China
关键词
miRNA-187; B-cell lymphoma 6; diffuse large B-cell lymphoma; apoptosis; multidrug resistance; NON-HODGKINS-LYMPHOMA; BREAST-CANCER; IN-VITRO; EXPRESSION; PROTEIN; PATHOGENESIS; MECHANISMS; MIR-187; GENES;
D O I
10.3892/ol.2016.4313
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MicroRNAs (miRs) are endogenous non-coding RNAs that serve key functions in a wide range of biological processes, including cell growth, development, apoptosis and carcinogenesis. However, the association between miR-187 and B-cell lymphoma 6 (BCL6) has yet to be fully investigated in lymphoma cell apoptosis. The present study hypothesized that a post-translational mechanism may exist for BCL6 expression, which is regulated by miR-187 in lymphoma cells. The present study demonstrated that the expression of miR-187 in diffuse large B-cell lymphoma (DLBCL) cells was significantly decreased, and its expression was negatively correlated with BCL6 expression. It was also observed that miR-187 directly binds to the 3-untranslated region of BCL6 mRNA and subsequently suppresses the expression of BCL6. Additionally, the induced expression of miR-187 significantly promoted DLBCL cell apoptosis in vitro. The drug sensitivity of human DLBCL SUDHL2 cells was increased following induction of miR-187 overexpression via an miR-187 mimic. In conclusion, the results of the present study suggest that the modulation of miR-187 expression in DLBCL cells may improve the sensitivity of chemotherapy through BCL6 targeting.
引用
收藏
页码:2845 / 2850
页数:6
相关论文
共 24 条
[1]   Validation of endogenous reference genes for RT-qPCR normalisation in bovine lymphoid cells (BL-3) infected with Bovine Viral Diarrhoea Virus (BVDV) [J].
Anstaett, Olivia L. ;
Brownlie, Joe ;
Collins, Margaret E. ;
Thomas, Carole J. .
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2010, 137 (3-4) :201-207
[2]   Expression of the BCL6 gene in the pre- and postnatal mouse [J].
Bajalica-Lagercrantz, S ;
Piehl, F ;
Farnebo, F ;
Larsson, C ;
Lagercrantz, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 247 (02) :357-360
[3]   Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1α (HIF-1α) [J].
Bos, R ;
van Diest, PJ ;
van der Groep, P ;
Greijer, AE ;
Hermsen, MA ;
Heijnen, I ;
Meijer, GA ;
Baak, JPA ;
Pinedo, HM ;
van der Wall, E ;
Shvarts, A .
ONCOGENE, 2003, 22 (55) :8948-8951
[4]   Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review [J].
Camicia, Rosalba ;
Winkler, Hans C. ;
Hassa, Paul O. .
MOLECULAR CANCER, 2015, 14
[5]   Identification of miR-187 and miR-182 as Biomarkers of Early Diagnosis and Prognosis in Patients with Prostate Cancer Treated with Radical Prostatectomy [J].
Casanova-Salas, Irene ;
Rubio-Briones, Jose ;
Calatrava, Ana ;
Mancarella, Caterina ;
Masia, Esther ;
Casanova, Juan ;
Fernandez-Serra, Antonio ;
Rubio, Luis ;
Ramirez-Backhaus, Miguel ;
Arminan, Ana ;
Dominguez-Escrig, Jose ;
Martinez, Francisco ;
Garcia-Casado, Zaida ;
Scotlandi, Katia ;
Vicent, Maria J. ;
Antonio Lopez-Guerrero, Jose .
JOURNAL OF UROLOGY, 2014, 192 (01) :252-259
[6]   A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo [J].
Cerchietti, Leandro C. ;
Yang, Shao Ning ;
Shaknovich, Rita ;
Hatzi, Katerina ;
Polo, Jose M. ;
Chadburn, Amy ;
Dowdy, Steven F. ;
Melnick, Ari .
BLOOD, 2009, 113 (15) :3397-3405
[7]   BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor [J].
Chang, CC ;
Ye, BH ;
Chaganti, RSK ;
DallaFavera, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (14) :6947-6952
[8]   Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2 [J].
Chao, A. ;
Lin, C-Y ;
Lee, Y-S ;
Tsai, C-L ;
Wei, P-C ;
Hsueh, S. ;
Wu, T-I ;
Tsai, C-N ;
Wang, C-J ;
Chao, A-S ;
Wang, T-H ;
Lai, C-H .
ONCOGENE, 2012, 31 (06) :764-775
[9]   FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas [J].
Duan, Shanshan ;
Cermak, Lukas ;
Pagan, Julia K. ;
Rossi, Mario ;
Martinengo, Cinzia ;
di Celle, Paola Francia ;
Chapuy, Bjoern ;
Shipp, Margaret ;
Chiarle, Roberto ;
Pagano, Michele .
NATURE, 2012, 481 (7379) :90-U100
[10]   The BCL6 proto-oncogene:: a leading role during germinal center development and lymphomagenesis [J].
Jardin, Fabrice ;
Ruminy, Philippe ;
Bastard, Christian ;
Tilly, Herve .
PATHOLOGIE BIOLOGIE, 2007, 55 (01) :73-83